AIDS Facts

Doctors are very cautious about giving medications to infected patients. In the US, the Department of Health and Human Services provides recommendations for employing anti-retroviral drugs that are based upon the latest information available and they also regularly updated.

 

Current guidelines to AIDS cure are focused on maximum symptom suppression. This approach is called “cocktails” or the HAART. The therapy aims to reduce the virus that is already present in the blood of patients to an extremely low or non-detectable level. However, the virus can’t be eliminated completely. For therapy, medical professionals recommend the use of three or more medications.

 

The guidelines also emphasize the value of the patient’s life. A patient should, therefore, be provided with a very simple but strong treatment regimen that has the least side effects. If you’re one of the patients, you need to be active in making decisions about your treatment. You need to be strong and determined. By consulting a medical professional, you will know the benefits and risks of such therapies.

CytoDyn - Fact File

 

CytoDyn, Inc. is a Colorado corporation with its home office in Santa Fe, NM. The Company's shares are quoted on the Pink Sheets under the symbol CYDY. CytoDyn periodically reports the financial condition and results of operations in the SEC Filings. "Cytolin®" and "CytoDyn" (as used to identify a particular class of products) are the registered trademarks of CytoDyn, Inc. The graphic logo is the registered mark of CytoDyn, Inc. Member New Mexico Biotechnology and Biomedical Association.

 

CytoDyn, is strongly committed to having Cytolin® approved by FDA. The said agency previously issued preliminary comments on the new product and CytoDyn, Inc has provided the FDA with a complete response to its preliminary comments. This resulted in the FDA backing off on some of their inappropriate demands. The company is now hoping to have further research conducted by the public sector, which usually has fewer problems with the FDA. Most drug companies have already spent millions to get FDA approval and this scenario is no different.

 

Cytolin® is completely different than the antivirals currently on the market, as this product is as an immune based therapy. There are approximately 11.5 million shares of freely traded stock on the market under CYDY from the parent company of CytoDyn, Inc., and anywhere from 12 to 15 million restricted shares, for a total of approximately 25 million shares.